Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 15Fallopian Tube Neoplasms 13Lung Neoplasms 11Melanoma 8Glioblastoma 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Carcinoma, Hepatocellular 7Urinary Bladder Neoplasms 6Triple Negative Breast Neoplasms 6Carcinoma, Renal Cell 6Uterine Cervical Neoplasms 4Pancreatic Neoplasms 4Breast Neoplasms 4Brain Neoplasms 4Prostatic Neoplasms 3Neoplasm Metastasis 3Nasopharyngeal Carcinoma 3Uveal Melanoma 2Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Rectal Neoplasms 2Oligodendroglioma 2Multiple Myeloma 2Medulloblastoma 2Lymphoma 2Liposarcoma 2Hematologic Neoplasms 2Gliosarcoma 2

Interventions

pembrolizumab 4Nivolumab 4durvalumab 3tremelimumab 1relatlimab 1fludarabine phosphate 1fludarabine 1avelumab 1atezolizumab 1Therapeutics 1Temozolomide 1Surgical Procedures, Operative 1Oxaliplatin 1Neoadjuvant Therapy 1Ipilimumab 1Injections 1Immunoglobulin G 1Docetaxel 1Disulfides 1Cyclophosphamide 1Chemotherapy, Adjuvant 1Capecitabine 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Microsatellite Instability × Immunoglobulin G × Clear all
NCT02966587 2018-01-17

Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

University of Washington

Phase 2 Withdrawn

Microsatellite Instability

Data powered by HemOnc (CC BY 4.0) Colophon âš¡